Related Experiment Video
Updated: Jun 25, 2025

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Association of Prenatal Exposure to Antiseizure Medications With Creative and Executive Function at Age 4.5 Years
Kimford J Meador1, Morris J Cohen1, David W Loring1
1From the Stanford University (K.J.M.), Palo Alto, CA; Pediatric Neuropsychology International (M.J.C.), Augusta; Emory University School of Medicine (D.W.L., E.G.), Atlanta, GA; The Emmes Company (A.G.M., C.A.B., C.R., A.C.), Rockville, MD; Piedmont University (S.S.), Athens, GA; University of Minnesota (A.K.B.), Minneapolis; University of Southern California (L.A.K.), Los Angeles; Brigham and Women's Hospital (P.E.V.), Harvard Medical School, Boston, MA; Northwestern University (E.E.G.), Chicago, IL; Minnesota Epilepsy Group (J.H.), Roseville; University of Cincinnati (J.C.), OH; Wake Forest University (M.S.), Winston-Salem, NC; Northwell Health (S.T.H.), Great Neck; Columbia University (A.M.P.), New York, NY; University of Washington (J.J.T.), Seattle; and University of Pittsburgh (P.B.P.), PA.
Insights
Fetal exposure to newer antiseizure medications (ASMs) in women with epilepsy (WWE) did not affect child creativity. However, executive functions showed exposure-dependent effects, particularly with levetiracetam, suggesting careful ASM dosing is crucial for fetal development.
Area of Science:
- Neuroscience
- Developmental Psychology
- Pharmacology
Background:
- Fetal exposure to antiseizure medications (ASMs) can impact neurodevelopment, but effects of newer ASMs on creativity and executive functions are not well understood.
- Previous research indicated adverse effects of valproate on these functions.
- This study investigates the impact of newer ASMs on creativity and executive functions in children exposed prenatally.
Purpose of the Study:
- To compare creativity and executive functions in children of women with epilepsy (WWE) exposed to ASMs versus children of healthy women (HW).
- To examine exposure-dependent effects of ASMs during the third trimester on these neurodevelopmental outcomes.
- To assess the impact of specific ASMs, including levetiracetam, on executive functions.
Main Methods:
- Prospective observational cohort study (Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs).
- Assessment of creativity (Torrance Test of Creative Thinking) and executive functions (Behavior Rating Inventory of Executive Function-Preschool Version) in 4.5-year-old children.
- Analysis of ASM exposure using concentration and defined daily dose ratios, with adjustments for confounding factors.
Main Results:
- No significant differences in creativity or executive function were observed between children of WWE and HW.
- No ASM exposure-dependent effects were found for creativity measures.
- Exposure-dependent effects on executive function were identified in children of WWE, particularly with levetiracetam, based on ASM concentration and defined daily dose ratios.
Conclusions:
- Fetal exposure to newer ASMs does not appear to affect creative thinking at 4.5 years.
- Executive function in children exposed to ASMs in utero shows dependency on ASM exposure levels.
- Optimizing ASM dosing to balance seizure control and minimize fetal risks, especially with medications like levetiracetam, is essential.
Background And Objectives:
Neurodevelopmental effects of fetal antiseizure medication (ASM) exposure on creativity and executive functions are poorly understood. We previously found fetal valproate exposure to adversely affect measures of creativity and executive functions. In this study, we examine fetal exposure of newer ASMs on these functions in children of women with epilepsy (WWE) compared with children of healthy women (HW).
Methods:
The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs study is a multicenter NIH-funded prospective observational cohort study of WWE and HW enrolled in pregnancy and their offsprings. This report examines blindly assessed creativity and executive functions in 4.5-year-old children of WWE vs HW. In addition, exposure-dependent ASM effects during the third trimester were examined in children of WWE, using a ratio of maximum observed ASM concentrations and ratio of defined daily dose (ratio DDD). For polytherapy, ratios were summed across ASMs. Linear regression models adjusted for multiple potential confounding factors were conducted for all analyses. The primary outcome for 4.5-year-old children was the Torrance Test of Creative Thinking-Figural Creativity Index. Secondary outcomes included the Global Executive Composite Score from the Behavior Rating Inventory of Executive Function-Preschool Version and subscales and other indexes of both measures.
Results:
The primary analysis included 251 children of WWE and 73 of HW. No differences in creativity or executive function were found between children of WWE vs HW. No ASM exposure-dependent effects were found for the creativity measures, but exposure-dependent effects for executive function were present for ratio ASM concentration and ratio DDD.
Discussion:
Our findings at 4.5 years show no differences in creative thinking between children of WWE vs HW (-3.2 [-9.0 to 2.7], p = 0.286) or associations with fetal exposure to ASMs (-2.6 [-11.0 to 5.7], p = 0.530). Secondary analyses revealed fetal exposure-dependent effects for executive function in children of WWE (7.0 [2.9-11.2], p = 0.001), which are most marked for levetiracetam (12.9 [4.2-21.6], p = 0.004). Our findings suggest that even for relatively safe ASMs, dosing needs to be adjusted to concentrations that prevent seizures, but balance risks to the fetus that high concentrations may pose.
Trial Registration Information:
The study is registered at ClinicalTrials.gov as NCT01730170.
Related Concept Videos
Information Processing Approach
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....

